IMUX240719P2500
- 0.82
- 0.000.00%
Immunic Newsroom
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
Immunic Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)
Hold Rating on Immunic: Balancing Long-Term Potential Against Short-Term Uncertainties
Buy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial Runway
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Immunic (IMUX)
Wedbush Maintains Outperform on Immunic, Raises Price Target to $7
Immunic Analyst Ratings
Buy Rating Assigned to Immunic Following Promising Interim Results of IMU-838 in Progressive Multiple Sclerosis Treatment
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Amgen (AMGN) and Neurocrine (NBIX)
Wedbush Sticks to Its Buy Rating for Immunic (IMUX)
Immunic Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Pro Medicus Limited (OtherPMCUF) and Immunic (IMUX)
Wedbush Keeps Their Buy Rating on Immunic (IMUX)
Immunic (IMUX) Receives a Rating Update From a Top Analyst
Immunic (IMUX) Receives a Rating Update From a Top Analyst
Wedbush Keeps Their Buy Rating on Immunic (IMUX)
Piper Sandler Gives a Buy Rating to Immunic (IMUX)